J Appl Biomed 18:61-69, 2020 | DOI: 10.32725/jab.2020.005
Association of FGF19, FGF21 and FGF23 with carbohydrate metabolism parameters and insulin resistance in patients with chronic kidney disease
- 1 Pomeranian Medical University, Clinical Department of Nephrology, Transplantology and Internal Medicine, Szczecin, Poland
- 2 Pomeranian Medical University, Department of Biochemistry and Medical Chemistry, Szczecin, Poland
- 3 Pomeranian Medical University, Department of Physiology, Szczecin, Poland
- 4 Warsaw Medical University, Department of Nephrology, Dialysis and Internal Medicine, Warsaw, Poland
Insulin resistance (IR) is characterised by increased gluconeogenesis in the liver and the resistance of peripheral receptors to insulin. Several factors, including IR, type 2 diabetes, new-onset diabetes after transplant (NODAT) and secondary parathyroidism, are related to chronic kidney disease (CKD). These factors are associated with higher mortality due to the increased risk of cardiovascular complications. Many factors have been identified as potential markers of IR in CKD. These factors include fibroblast growth factors (FGFs), a subfamily of endocrine polypeptides. In this study, we examined the association of FGF19, FGF21 and FGF23 with selected parameters related to carbohydrate metabolism and insulin resistance in non diabetic patients with predialysis CKD and in non diabetic patients after renal transplantation. The study included 108 non diabetic subjects: 40 patients with predialysis CKD, 45 patients with CKD who had undergone renal transplantation, and 23 healthy subjects (control group). In patients who had undergone renal transplantation, concentrations of FGF23 were increased compared to the control group and patients with predialysis CKD. The highest and lowest FGF19 concentrations were observed in CKD patients and in patients who had undergone kidney transplantation, respectively. This difference was statistically significant. Leptin concentrations were higher in CKD patients compared to the control group and patients who had undergone kidney transplantation. There were no statistically significant differences in adiponectin concentrations, lean body mass or fat tissue mass between the studied groups. HOMA-IR and insulin levels were significantly increased in CKD patients and in patients who had undergone renal transplantation in comparison to the control group. The results of the study suggest the involvement of FGF in carbohydrate metabolism and insulin resistance in patients with predialysis CKD, as well as a correlation with kidney function.
Keywords: Body composition; Chronic kidney disease; FGF19; FGF21; FGF23; Insulin
Grants and funding:
This work was supported by the National Centre of Science in Poland under grant number N402 564040.
Conflicts of interest:
The authors declare that they have no conflicts of interests.
Received: April 1, 2019; Revised: December 27, 2019; Accepted: February 11, 2020; Prepublished online: February 28, 2020; Published: August 27, 2020 Show citation
ACS | AIP | APA | ASA | Harvard | Chicago | Chicago Notes | IEEE | ISO690 | MLA | NLM | Turabian | Vancouver |
References
- Anuwatmatee S, Tang S, Wu BJ, Rye KA, Ong KL (2019). Fibroblast growth factor 21 in chronic kidney disease. Clin Chim Acta 489: 196-202. DOI: 10.1016/j.cca.2017.11.002.
Go to original source...
Go to PubMed...
- Asrih M, Veyrat-Durebex C, Poher AL, Lyautey J, Rohner-Jeanrenaud F, Jornayvaz FR (2016). Leptin as a Potential Regulator of FGF21. Cell Physiol Biochem 38(3): 1218-1225. DOI: 10.1159/000443070.
Go to original source...
Go to PubMed...
- Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y, et al. (2008). Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149(12): 6018-6027. DOI: 10.1210/en.2008-0816.
Go to original source...
Go to PubMed...
- Degirolamo C, Sabbà C, Moschetta A (2016). Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat Rev Drug Discov 15(1): 51-69. DOI: 10.1038/nrd.2015.9.
Go to original source...
Go to PubMed...
- Fayed A, El Nokeety MM, Heikal AA, Abdulazim DO, Naguib MM, El Din UAAS (2018). Fibroblast growth factor-23 is a strong predictor of insulin resistance among chronic kidney disease patients. Ren Fail 40(1): 226-230. DOI: 10.1080/0886022X.2018.1455594.
Go to original source...
Go to PubMed...
- Fernandes-Freitas I, Owen BM (2015). Metabolic roles of endocrine fibroblast growth factors. Curr Opin Pharmacol 25: 30-35. DOI: 10.1016/j.coph.2015.09.014.
Go to original source...
Go to PubMed...
- Fliser D, Pacini G, Engelleiter R, Kautzky-Willer A, Prager R, Franek E, et al. (1998). Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 53(5): 1343-1347. DOI: 10.1046/j.1523-1755.1998.00898.x.
Go to original source...
Go to PubMed...
- Fukumoto S (2008). Actions and mode of actions of FGF19 subfamily members. Endocr J 55(1): 23-31. DOI: 10.1507/endocrj.kr07e-002.
Go to original source...
Go to PubMed...
- Gaich G, Chien JY, Fu H, Glass LC, Deeg MA, Holland WL, et al. (2013). The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 18(3): 333-340. DOI: 10.1016/j.cmet.2013.08.005.
Go to original source...
Go to PubMed...
- Garland JS, Holden RM, Ross R, Adams MA, Nolan RL, Hopman WM, et al. (2014). Insulin resistance is associated with Fibroblast Growth Factor-23 in stage 3-5 chronic kidney disease patients. J Diabetes Complications 28(1) 61-65. DOI: 10.1016/j.jdiacomp.2013.09.004.
Go to original source...
Go to PubMed...
- Han SH, Choi SH, Cho BJ, Lee Y, Lim S, Park YJ, et al. (2010). Serum fibroblast growth factor-21 concentration is associated with residual renal function and insulin resistance in end-stage renal disease patients receiving long-term peritoneal dialysis. Metabolism 59(11): 1656-1662. DOI: 10.1016/j.metabol.2010.03.018. DOI: 10.1371/journal.pone.0122885.
Go to original source...
Go to PubMed...
- Hanks LJ, Casazza K, Judd SE, Jenny NS, Gutiérrez OM (2015). Associations of fibroblast growth factor-23 with markers of inflammation, insulin resistance and obesity in adults. PLoS One 10(3): e0122885. DOI: 10.1371/journal.pone.0122885.
Go to original source...
Go to PubMed...
- Hu X, Xiong Q, Xu Y, Zhang X, Pan X, Ma X, et al. (2018). Association of serum fibroblast growth factor 19 levels with visceral fataccumulation is independent of glucose tolerance status. Nutr Metab Cardiovasc Dis 28(2): 119-125. DOI: 10.1016/j.numecd.2017.10.009.
Go to original source...
Go to PubMed...
- Hui Q, Jin Z, Li X, Liu C, Wang X (2018). FGF Family: From Drug Development to Clinical Application. Int J Mol Sci 19(7) pii: E1875. DOI: 10.3390/ijms19071875.
Go to original source...
Go to PubMed...
- Isakova T, Cai X, Lee J, Xie D, Wang X, Mehta R, et al. (2018). Longitudinal FGF23 Trajectories and Mortality in Patients with CKD. J Am Soc Nephrol 29(2): 579-590. DOI: 10.1681/ASN.2017070772.
Go to original source...
Go to PubMed...
- Kharitonenkov A, Shanafelt AB (2009). FGF21: a novel prospect for the treatment of metabolic diseases. Curr Opin Investig Drugs 10(4): 359-364. PMID: 19337957.
Go to PubMed...
- Kliewer SA, Mangelsdorf DJ (2015). Bile Acids as Hormones: The FXR-FGF15/19 Pathway. Dig Dis 33(3): 327-331. DOI: 10.1159/000371670.
Go to original source...
Go to PubMed...
- Kurşat S, Colak HB, Toraman A, Tekçe H, Ulman C, Bayturan O (2010). Relationship of insulin resistance in chronic haemodialysis patients with inflammatory indicators, malnutrition, echocardiographic parameters and 24 hour ambulatory blood pressure monitoring. Scand J Urol Nephrol 44(4): 257-264. DOI: 10.3109/00365591003733682.
Go to original source...
Go to PubMed...
- Lin Z, Tian H, Lam KS, Lin S, Hoo RC, Konishi M, et al. (2013). Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab 17(5): 779-789. DOI: 10.1016/j.cmet.2013.04.005.
Go to original source...
Go to PubMed...
- Lin Z, Wu Z, Yin X, Liu Y, Yan X, Lin S, et al. (2010). Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS One 5(12): e15534. DOI: 10.1371/journal.pone.0015534.
Go to original source...
Go to PubMed...
- Liu S, Quarles LD (2007). How fibroblast growth factor 23 works. J Am Soc Nephrol 18(6): 1637-1647. DOI: 10.1681/ASN.2007010068.
Go to original source...
Go to PubMed...
- Marchelek-Myśliwiec M, Dziedziejko V, Nowosiad-Magda M, Dołęgowska K, Dołęgowska B, Pawlik A, et al. (2019a). Chronic kidney disease is associated with increased plasma levels of fibroblast growth factors 19 and 21. Kidney Blood Press Res 44: 1207-1218. DOI: 10.1159/000502647.
Go to original source...
Go to PubMed...
- Marchelek-Myśliwiec M, Dziedziejko V, Nowosiad-Magda M, Wiśniewska M, Safranow K, Pawlik A, et al. (2019b). Bone metabolism parameters in haemodialysis patients with chronic kidney disease and in patients after kidney transplantation. Physiol Res 68(6): 947-954. DOI: 10.33549/physiolres.934118.
Go to original source...
Go to PubMed...
- Mraz M, Bartlova M, Lacinova Z, Michalsky D, Kasalicky M, Haluzikova D, et al. (2009). Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf) 71(3): 369-375. DOI: 10.1111/j.1365-2265.2008.03502.x.
Go to original source...
Go to PubMed...
- Nishimura T, Nakatake Y, Konishi M, Itoh N (2000). Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 1492(1): 203-206. DOI: 10.1016/s0167-4781(00)00067-1.
Go to original source...
Go to PubMed...
- Reiche M, Bachmann A, Lössner U, Blüher M, Stumvoll M, Fasshauer M (2010). Fibroblast growth factor 19 serum levels: relation to renal function and metabolic parameters. Horm Metab Res 42(3): 178-181. DOI: 10.1055/s-0029-1243249.
Go to original source...
Go to PubMed...
- Sit D, Tanriverdi E, Kayabasi H, Erdem M, Sari H (2018). Is FGF23 effective on insulin resistance in individuals with metabolic syndrome? Horm Mol Biol Clin Investig 35(2) pii: /j/hmbci.2018.35.issue-2/hmbci-2018-0018/hmbci-2018-0018.xml. DOI: 10.1515/hmbci-2018-0018.
Go to original source...
Go to PubMed...
- Spoto B, Pisano A, Zocalli C (2016). Insulin resistance in chronic kidney disease: a systematic review. Am J Physiol Renal Physiol 311(6): F1087-F1108. DOI: 10.1152/ajprenal.00340.2016.
Go to original source...
Go to PubMed...
- Stein S, Bachmann A, Lössner U, Kratzsch J, Blüher M, Stumvoll M, et al. (2009). Serum levels of the adipokine FGF21 depend on renal function. Diabetes Care 32(1): 126-128. DOI: 10.2337/dc08-1054.
Go to original source...
Go to PubMed...
- Strowski MZ (2017). Impact of FGF21 on glycemic control. Horm Mol Biol Clin Investig 30(2) pii: /j/hmbci.2017.30.issue-2/hmbci-2017-0001/hmbci-2017-0001.xml. DOI: 10.1515/hmbci-2017-0001.
Go to original source...
Go to PubMed...
- Suassuna PGA, de Paula RB, Sanders-Pinheiro H, Moe OW, Hu MC (2019). Fibroblast growth factor 21 in chronic kidney disease. J Nephrol 32(3): 365-377. DOI: 10.1007/s40620-018-0550-y.
Go to original source...
Go to PubMed...
- Tanajak P, Pongkan W, Chattipakorn SC, Chattipakorn N (2018). Increased plasma FGF21 level as an early biomarker for insulin resistance and metabolic disturbance in obese insulin-resistant rats. Diab Vasc Dis Res 15(3): 263-269. DOI: 10.1177/1479164118757152.
Go to original source...
Go to PubMed...
- Tomlinson E, Fu L, John L, Hultgren B, Huang X, Renz M, et al. (2002). Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143(5): 1741-1747. DOI: 10.1210/endo.143.5.8850.
Go to original source...
Go to PubMed...
- Voytovich MH, Asberg A, Hjelmesaeth J, Jenssen T, Hartmann A (2006). Association between insulin resistance and endothelialdysfunction in renal transplant recipients. Clin Transplant 20(2): 195-199. DOI: 10.1111/j.1399-0012.2005.00465.x.
Go to original source...
Go to PubMed...
- Wojcik M, Dolezal-Oltarzewska K, Janus D, Drozdz D, Sztefko K, Starzyk JB (2012). FGF23 contributes to insulin sensitivity in obese adolescents - preliminary results. Clin Endocrinol (Oxf) 77(4): 537-540. DOI: 10.1111/j.1365-2265.2011.04299.x.
Go to original source...
Go to PubMed...
- Zaheer S, de Boer IH, Allison M, Brown JM, Psaty BM, Robinson-Cohen C, et al. (2017). Fibroblast Growth Factor 23, Mineral Metabolism, and Adiposity in Normal Kidney Function. J Clin Endocrinol Metab 102(4): 1387-1395. DOI: 10.1210/jc.2016-3563.
Go to original source...
Go to PubMed...
- Zhang F, Yu L, Lin X, Cheng P, He L, Li X, et al. (2015). Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic Diseases. Mol Endocrinol 29(10): 1400-1413. DOI: 10.1210/me.2015-1155.
Go to original source...
Go to PubMed...
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.